Do You Need a License to Sell Peptides in Georgia?

There is no single "peptide license" that a business applies for and receives. Whether your company needs a license depends on which lane you are operating in: ordinary business formation and sales tax registration, licensure tied to distributing drugs or devices intended for human use, or the supply of research-use-only (RUO) materials sold business-to-business for laboratory and research purposes. Those are three distinct regulatory questions with three distinct answers, and treating them as one question is where most new peptide sellers get into difficulty. This article is informational only and is not legal advice — the answer for your entity, your catalog, and your customer base belongs with your own attorney and the relevant state board.

The three questions hiding inside one

When an operator asks whether a license is required, they are usually asking one of three things without realizing it.

The first is the ordinary commerce question: what does any business need in order to legally exist, collect sales tax, and hold inventory? That is entity formation, registration with the appropriate state agency, a sales tax number if you are selling taxable goods, and whatever local business or occupational registration applies where you operate. This lane has nothing to do with peptides specifically. Every reseller, whether they sell reagents or running shoes, answers it the same way.

The second is the regulated-product question: does the specific thing you intend to sell fall into a category the state or federal government licenses separately? Distribution of prescription drugs, controlled substances, and certain devices sits inside licensing regimes with their own applications, facility requirements, recordkeeping obligations, and inspection exposure. Whether a given compound in a given presentation lands inside one of those regimes is a legal determination, not a marketing decision — and it is not one you should make from a forum post or a supplier's sales page.

The third is the representation question, and it is the one most businesses underestimate. Regulatory categorization does not follow the molecule alone. It follows what you say the product is for, who you sell it to, how it is labeled, and what claims travel with it. The same material can sit in very different regulatory positions depending on whether it is supplied as a research reagent to a business or presented as something intended for people. Your marketing copy, your product pages, your sales conversations, and your packaging are all part of the record.

Why the framework is not a single rule you can look up

Operators want a citation — a rule number that says yes or no. That is not how this area works, and any supplier who hands you one should be treated with suspicion.

Drug and device regulation operates at the federal level; professional licensure, facility licensure, and distribution licensure are largely administered at the state level and vary meaningfully from one state to the next. Layered on top of that are professional practice rules governing what licensed practitioners may do, corporate practice doctrines governing who may own certain entities, and local registration requirements. A definitive answer requires someone to look at your actual entity structure, your actual catalog, and your actual customer type against all of those layers at once.

What you can do productively is understand which questions determine the answer, so that the hour you spend with counsel is efficient rather than exploratory.

Notice that none of these rows resolves to a universal yes or no. That is the honest state of the landscape, and a supplier telling you otherwise is selling you confidence rather than information.

What research-use-only actually obligates you to do

Research-use-only is not a disclaimer you paste at the bottom of a page. It is a description of what the material is, who it is sold to, and how it is handled — and it only holds up if your entire operation is consistent with it.

In practice, that consistency means several things. Product pages describe the compound and the science, not outcomes for people. There is no dosing information, no administration guidance, no protocol content, and no before-and-after framing anywhere in your funnel. Sales conversations do not quietly contradict the website. Packaging and labeling carry research-use language rather than anything resembling patient-facing instructions. Compounds are not bundled with supplies in a way that presents as a ready-to-use kit for a person.

RUO materials are not FDA-approved drugs and are not intended for human consumption. That is a statement about the product category, and it has to remain true in every place a customer encounters your brand. Where published research is relevant to your buyers, describe it as research — studies indicate, research suggests — and keep the discussion on compound science rather than promised results.

The practical takeaway for a reseller is this: your compliance posture is built from your own materials, not inherited from your supplier. A supplier can give you accurate documentation and clean labeling. It cannot make your website say the right things.

The questions to take to counsel before you buy inventory

Go into the conversation with a written list. Broadly, the ground you want covered includes:

Entity and registration. Is your structure appropriate for the catalog you intend to carry? What state and local registrations attach to holding and shipping inventory? Does your sales tax position change if you ship across state lines?

Product categorization. For each category you plan to stock, how would a regulator likely characterize it given your intended customers and your marketing? What presentation choices push a product from one category into another?

Customer verification. How will you confirm that your buyers are the type of customer you are permitted to sell to, and what documentation should you retain? What does your intake or account-approval process need to capture?

Marketing review. Who reviews your product copy, ads, and email before it goes live? What language is off-limits, and what is your process when a staff member writes something that crosses the line?

Recordkeeping. What documentation should you keep on incoming inventory — certificates of analysis, batch identifiers, supplier records — and for how long? If you ever need to trace a batch, can you?

Insurance and contracts. What coverage does your model call for, and what do your supplier terms actually say about the documentation you receive?

None of that requires you to become a regulatory expert. It requires you to arrive prepared so that counsel can answer precisely instead of generally.

Vetting a supplier: what to verify and what to walk away from

Once the legal side is scoped, supplier diligence becomes the operational question. A few things separate a serious wholesale partner from a storefront.

Start with testing. Ask what analytical methods are used, what the purity standard is, and what else is screened beyond identity and purity. Ask whether testing is per batch or occasional. Then ask the question that actually matters: can you see the results before you buy, and can you match a certificate to the specific lot in your hands? Testing that cannot be independently reviewed is a claim, not evidence.

Next, pricing transparency. Programs that hide tier pricing behind a sales call, or that reveal minimums only after you have submitted an application, are structurally designed to make comparison difficult. You should be able to model your landed cost before you commit.

Watch for suppliers that treat documentation as a revenue line — charging separately for certificates of analysis, or providing them only on request for select orders. Documentation is a cost of doing business for a legitimate supplier, not an upsell.

Finally, look at fulfillment and consistency. Where does the product ship from? Is lot-to-lot consistency documented? What happens when a batch fails? A supplier who cannot describe their failure process has probably never thought about it.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around removing exactly those unknowns.

Every compound meets a 99%+ HPLC purity standard, and every batch goes through six-panel testing rather than spot-checking. Certificates of analysis are publicly verifiable — buyers can review lab results themselves rather than requesting them, paying for them, or accepting a screenshot. That distinction matters most on the days something goes wrong, because verifiable documentation is what lets a business trace a batch without depending on a supplier's goodwill.

Fulfillment is handled from within the United States, with orders shipping in five to seven days. Wholesale pricing tiers are presented directly, so a prospective partner can model cost before committing to anything. The application itself is a three-step process rather than an open-ended sales cycle.

All compounds are supplied for research use only. Real Peptides does not position products as therapeutics, does not provide dosing or administration guidance, and does not make outcome claims — a posture that protects the buyer's business as much as the supplier's.

Where to go from here

If your entity is formed, your categorization questions are scoped with counsel, and your marketing is consistent with research-use-only supply, the remaining step is choosing a supplier whose documentation you can actually verify. The Wholesale Partner Program application is built for operators at that stage: transparent tiers, published lab results, and a straightforward path to a first order.

For more detail, see the wholesale peptides program overview, the broader guide to do you need a license to sell peptides, or apply for a wholesale account.